This increased susceptibility is driven by the CXCL-8 chemokine, which exhibited significantly elevated levels in the plasma of CLL patients and correlated with the ability to release NETs after neutrophil activation. This evidence concerns the gene CXCL8 and B-cell chronic lymphocytic leukemia.